In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 ...

A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...

Biopharmaceuticals: Redefining the Future of Modern MedicineThe Global Bio Pharmaceuticals Market is valued at USD 421.58 ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a ...

An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

Agreement with IRRI marks Pairwise's third CGIAR partnership, enabling the research institute to use Fulcrum® genome editing technology to develop higher-yielding, more nutritious rice varieties that ...

Liver cells are indispensable for research—for drug testing, to better understand diseases such as hepatitis, fatty liver, cirrhosis, or liver cancer and for development of future cell therapies.

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...

T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...